Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 11, Number 1, February 2018, pages 41-45

Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center

**Table 1.** Summary Statistics (Infliximab vs. Vedolizumab)
	Infliximab (N = 27 )	Vedolizumab (N = 32)	P-value
STD: standard deviation; 5-ASA: 5-aminosalicylates; PPI: proton pump inhibitor; BMI: body mass index.
Age in year, mean (STD)	42.3 (18.5)	54.5 (17.9)	0.0135
DOD	5.8 (5.8)	6.6 (8.6)	0.6682
Race, %			0.6692
Non-Hispanic white	18 (66.7)	21 (65.6)
Black	7 (25.9)	10 (31.2)
Other	2 (7.4)	1 (3.1)
Gender			1.0000
0 (male)	11 (40.7)	14 (43.8)
1 (female)	16 (59.3)	18 (56.2)
Nicotine use	1 (3.7)	2 (6.3)	1.0000
Steroid use	8 (29.6)	5 (15.6)	0.1587
5-ASA	18 (66.7)	15 (46.9)	0.1086
Thiopurine	7 (25.9)	10 (31.3)	0.7756
Methotrexate	3 (11.1)	2 (6.2)	0.6523
TNF blocker experienced	6 (22.2)	19 (59.4)	0.0076
Vedolizumab exp.	3 (11.1)	0 (0)	0.0900
Vitamin D def.	7 (25.9)	11 (34.4)	0.1059
PPI use	3 (11.1)	6 (18.8)	0.4877
BMI	25.7 (5.3)	25.8 (5.4)	0.5440
Duration of clinical follow-up after induction, mean (weeks)	12.38	15
Clinical response	18 (66.7%)	25 (78.1%)	0.3861

Table 1. Summary Statistics (Infliximab vs. Vedolizumab)

Infliximab (N = 27 )

Vedolizumab (N = 32)

P-value

STD: standard deviation; 5-ASA: 5-aminosalicylates; PPI: proton pump inhibitor; BMI: body mass index.

Age in year, mean (STD)

42.3 (18.5)

54.5 (17.9)

0.0135

DOD

5.8 (5.8)

6.6 (8.6)

0.6682

Race, %

0.6692

Non-Hispanic white

18 (66.7)

21 (65.6)

Black

7 (25.9)

10 (31.2)

Other

2 (7.4)

1 (3.1)

Gender

1.0000

0 (male)

11 (40.7)

14 (43.8)

1 (female)

16 (59.3)

18 (56.2)

Nicotine use

1 (3.7)

2 (6.3)

1.0000

Steroid use

8 (29.6)

5 (15.6)

0.1587

5-ASA

18 (66.7)

15 (46.9)

0.1086

Thiopurine

7 (25.9)

10 (31.3)

0.7756

Methotrexate

3 (11.1)

2 (6.2)

0.6523

TNF blocker experienced

6 (22.2)

19 (59.4)

0.0076

Vedolizumab exp.

3 (11.1)

0 (0)

0.0900

Vitamin D def.

7 (25.9)

11 (34.4)

0.1059

PPI use

3 (11.1)

6 (18.8)

0.4877

BMI

25.7 (5.3)

25.8 (5.4)

0.5440

Duration of clinical follow-up after induction, mean (weeks)

12.38

Clinical response

18 (66.7%)

25 (78.1%)

0.3861

**Table 2.** Rate Ratios for Clinical Response
	Proportion with response	Number with response	Number of total person weeks	Response rate (no. with response/PW)*	IRR (95% CI)
*Response rate per 100 person-weeks. IRR: incidence rate ratio; CI: confidence interval.
Overall	43/59 (72.9%)	43	814
Infliximab	18/27 (66.7%)	18	334	5.38	1
Vedolizumab	25/32 (78.1%)	25	480	5.21	0.97 (0.53 - 1.77)

Table 2. Rate Ratios for Clinical Response

Proportion with response

Number with response

Number of total person weeks

Response rate (no. with response/PW)*

IRR (95% CI)

*Response rate per 100 person-weeks. IRR: incidence rate ratio; CI: confidence interval.

Overall

43/59 (72.9%)

814

Infliximab

18/27 (66.7%)

334

5.38

Vedolizumab

25/32 (78.1%)

480

5.21

0.97 (0.53 - 1.77)

**Table 3.** Rate Ratios for TNF Blocker Naive Patients
	Proportion with response	Response rate (number with response/PW)*	IRR (95% CI)
*Response rate per 100 person-weeks. IRR: incidence rate ratio; CI: confidence interval.
Infliximab	16/21 (76.2%)	6.48	1
Vedolizumab	10/13 (76.9%)	6.74	1.04 (0.47 - 2.29)

Table 3. Rate Ratios for TNF Blocker Naive Patients

Proportion with response

Response rate (number with response/PW)*

IRR (95% CI)

*Response rate per 100 person-weeks. IRR: incidence rate ratio; CI: confidence interval.

Infliximab

16/21 (76.2%)

6.48

Vedolizumab

10/13 (76.9%)

6.74

1.04 (0.47 - 2.29)

**Table 4.** Rate Ratios for TNF Blocker Experienced Patients
Clinical cohort	Proportion with response	Response rate (number with response/PW)*	IRR (95% CI)
*Response rate per 100 person-weeks.
Infliximab	2/6 (33.3%)	2.29	1
Vedolizumab	15/19 (78.9%)	4.52	1.97 (0.45 - 8.63)

Table 4. Rate Ratios for TNF Blocker Experienced Patients

Clinical cohort

Proportion with response

Response rate (number with response/PW)*

IRR (95% CI)

*Response rate per 100 person-weeks.

Infliximab

2/6 (33.3%)

2.29

Vedolizumab

15/19 (78.9%)

4.52

1.97 (0.45 - 8.63)